Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 201.7% | -55.2% | -71.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 35.5% | -24.4% | 81.7% | 96.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -971.7% | -2,511.5% | -816.8% | -97.1% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -187% | -482.3% | -1,071.9% | 38.1% |
| EPS | -0.17 | -0.18 | -0.73 | 0.09 |
| % Growth | 5.6% | 75.3% | -912% | – |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | -$0 | $0 | -$0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,334.5% | -3,622.3% | -801.5% | -158.8% |